BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
8.80
+0.01 (0.11%)
At close: Apr 28, 2026, 4:00 PM EDT
8.97
+0.17 (1.93%)
After-hours: Apr 28, 2026, 6:08 PM EDT
BBOT Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for BBOT stock have an average target of 24, with a low estimate of 20 and a high estimate of 29. The average target predicts an increase of 172.73% from the current stock price of 8.80.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 6, 2026.
Analyst Ratings
The average analyst rating for BBOT stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 3 | 4 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $29 | Strong Buy | Maintains | $27 → $29 | +229.55% | Mar 6, 2026 |
| Stifel | Stifel | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +161.36% | Feb 11, 2026 |
| Raymond James | Raymond James | Buy Initiates $24 | Buy | Initiates | $24 | +172.73% | Jan 9, 2026 |
| Wedbush | Wedbush | Buy Reiterates $25 | Buy | Reiterates | $25 | +184.09% | Dec 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $20 | Buy | Initiates | $20 | +127.27% | Dec 5, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.26
from -4.30
EPS Next Year
-2.22
from -2.26
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.96 | -1.87 | ||||||
| Avg | -2.26 | -2.22 | ||||||
| Low | -2.56 | -2.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.